Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (193)	10/1/2002 4:41:08 AM
From: Icebrg	Read Replies (1) \| Respond to of 204

>>Might it not have been cheaper for GPC to buy the company ?>> Why take on a lot of problems if they don't have to. Apart from that. The market cap of NEOT is only 1,4 mUSD. So, when GPC makes their 1 mUSD investment next year they will get a fair chunk, if share prices stay where they are now (which they of course never do). As NEOT has now given away satraplatin one has to wonder what they are going to work on in the future. Outlicensing the neurological compounds perhaps. The 2 mUSD collected from GPC will only last 4 months at their projected burn rate of 0,5 mUSD per month. Although GPC will most probably cover some of the burden as part of the development costs they will carry. Ice